Literature DB >> 11836704

Diagnostic utility of Glut-1 and CA 15-3 in discriminating adenocarcinoma from hepatocellular carcinoma in liver tumors biopsied by fine-needle aspiration.

Robert L Zimmerman1, Melissa Burke, Nancy A Young, Charalambos C Solomides, Marluce Bibbo.   

Abstract

BACKGROUND: Diagnosing liver tumors can be difficult in the setting of a poorly differentiated tumor or tumors with no known prior malignancy. Frequently, alpha-fetoprotein, carcinoembryonic antigen, factor VIII, and mucicarmine have been employed to distinguish hepatocellular carcinoma (HCC) from adenocarcinoma. However, these stains have their limitations. CA 15-3 and Glut-1 are expressed in a variety of carcinomas. To the authors' knowledge, their expression in HCC has not been studied extensively. The authors examined the clinical utility of CA 15-3 and Glut-1 in the setting of fine-needle aspiration biopsy samples from the liver.
METHODS: Thirty-five cases of HCC and 59 cases of tumors metastatic to the liver were studied. These cases previously were studied with the hepatocyte paraffin-1 antibody. Each case was stained with CA 15-3 and Glut-1 using the avidin-biotin complex method. Each case was evaluated in a blinded fashion for membranous staining that was stronger than cytoplasmic or background staining. The diagnoses were unblinded and staining patterns were compared.
RESULTS: CA 15-3 stained 43 of 59 metastatic carcinoma samples and 3 of 35 HCC samples. Glut-1 stained 34 of 59 metastases and 2 of 35 HCCs. Together, the 2 immunostains stained 51 of 59 metastases and 5 of 35 HCCs. Diagnostic accuracy was improved by adding hepatocyte paraffin-1 to the staining panel.
CONCLUSIONS: CA 15-3 and Glut-1, especially in conjunction with hepatocyte paraffin-1, appear to be helpful in discriminating HCC from other carcinomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11836704     DOI: 10.1002/cncr.10309.abs

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Utility of FNAC in Conjunction with Cell Block for Diagnosing Space-Occupying Lesion (SOL) of Liver with Emphasis on Differentiating Hepatocellular Carcinoma from Metastatic SOL: Analysis of 61 Cases.

Authors:  Haq Sheefa; Jadhav Lata; Mubeen Basharat; Makhdoomi Rumana; Malhotra Veena
Journal:  Oman Med J       Date:  2016-03

2.  Utility of PET Scans in the Diagnosis and Management of Gastrointestinal Tumors.

Authors:  Nandakumar Menon; Mark Mandelkern
Journal:  Dig Dis Sci       Date:  2022-07-30       Impact factor: 3.487

3.  GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis.

Authors:  Thomas Amann; Ulrike Maegdefrau; Arndt Hartmann; Abbas Agaimy; Jörg Marienhagen; Thomas S Weiss; Oliver Stoeltzing; Christina Warnecke; Jürgen Schölmerich; Peter J Oefner; Marina Kreutz; Anja K Bosserhoff; Claus Hellerbrand
Journal:  Am J Pathol       Date:  2009-03-12       Impact factor: 4.307

4.  Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography.

Authors:  Jong Doo Lee; Mijin Yun; Jae Myun Lee; Youjeong Choi; Youn-Hee Choi; Ji Su Kim; Se Jong Kim; Kyung Sik Kim; Woo Ick Yang; Young Nyun Park; Kwang-Hyub Han; Woo Jung Lee; Naechun Yoo; Sang Moo Lim; Jeon Han Park
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-28       Impact factor: 9.236

5.  Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study.

Authors:  Ximin Shi; Haiqun Xing; Xiaobo Yang; Fang Li; Shaobo Yao; Jia Congwei; Haitao Zhao; Marcus Hacker; Li Huo; Xiang Li
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-10-24       Impact factor: 9.236

6.  Comparisons of Quantitative Parameters of Ga-68-Labelled Fibroblast Activating Protein Inhibitor (FAPI) PET/CT and [18F]F-FDG PET/CT in Patients with Liver Malignancies.

Authors:  Dheeratama Siripongsatian; Chetsadaporn Promteangtrong; Anchisa Kunawudhi; Peerapon Kiatkittikul; Natphimol Boonkawin; Chatchawarin Chinnanthachai; Attapon Jantarato; Chanisa Chotipanich
Journal:  Mol Imaging Biol       Date:  2022-04-29       Impact factor: 3.484

Review 7.  Clinical application of 18F-fluorodeoxyglucose positron emission tomography for assessment and evaluation after therapy for malignant hepatic tumor.

Authors:  Masakatsu Tsurusaki; Masahiko Okada; Hiroyuki Kuroda; Mitsuru Matsuki; Kazunari Ishii; Takamichi Murakami
Journal:  J Gastroenterol       Date:  2013-03-26       Impact factor: 7.527

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.